Review Article The efficacy of resistance training for non-alcoholic fatty-liver disease: a meta-analysis of randomized controlled trials

Yi Ye¹, Linglong Chen², Xiaoping Yang³

Departments of ¹Gastroenterology, ²Emergency, Wenzhou People's Hospital, Wenzhou 325000, Zhejiang Province, China; ³Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China

Received March 30, 2018; Accepted February 12, 2019; Epub December 15, 2019; Published December 30, 2019

Abstract: Introduction: The efficacy of resistance training to treat non-alcoholic fatty-liver disease (NAFLD) remains controversial. In this study, a systematic review and meta-analysis was performed to explore the influence of resistance training on NAFLD. Methods: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were search for dates through March 2018 for randomized controlled trials (RCTs) assessing the effect of resistance training on liver function of NAFLD. Meta-analysis was performed using the random-effect model. Results: Four RCTs involving 133 patients are included in the meta-analysis. Overall, compared with control group (i.e. usual activities or aerobic activities) for NAFLD, resistance training can significantly reduce alanine transferase (ALT) (mean difference (MD) = -6.63; 95% confidence interval (Cl) = -12.87 to -0.40; P = 0.04), aspartate transferase (AST) (MD = -1.17; 95% Cl = -1.82 to -0.52; P = 0.0004), gamma-glutamyl transferase (GGT) (MD = -2.87; 95% Cl = -5.20 to -0.54; P = 0.02), cholesterol (MD = -8.76; 95% Cl = -13.08 to -4.44; P < 0.0001), low-density lipoprotein (LDL) (MD = -5.06; 95% Cl = -6.25 to -3.87; P < 0.00001), but has no remarkable influence on glycosylated hemoglobin (HbA1C) (MD = -0.01; 95% Cl = -0.08 to 0.06; P = 0.81). Conclusions: Resistance exercise has an important ability to reduce ALT, AST, GGT, cholesterol, and LDL in patients with NAFLD, but shows no influence on HbA1C.

Keywords: Resistance training, non-alcoholic fatty-liver disease (NAFLD), liver function, randomized controlled trials, meta-analysis

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as a wide spectrum of disorders ranging from simple steatosis to progressive nonalcoholic steatohepatitis, hepatic fibrosis, and cirrhosis [1-3]. NAFLD causes elevated liver enzymes including alanine amino transferase (ALT) and aspartate amino transferase (AST) and build-up of fat within liver cells [4-7]. The incidence of NAFLD is about 20%-35% in the Western population, 19%-32% in Asian population, and 70%-90% in obese individuals [8, 9]. The severity of fatty liver is positively related to anthropometric measurements including body mass index, waist and hip circumference, subcutaneous adipose tissue thickness and hypertriglyceridaemia [10, 11].

There is no specific drug therapy approved for the treatment of NAFLD and current methods

are to treat "metabolic syndrome" rather than NAFLD as an individual entity [12-15]. Lifestyle change and physical activities are currently the main recommendation for people with NAFLD [16]. Exercise training is a major component of treatment for NAFLD as recommended by the American Gastroenterological Association [17, 18]. Exercise training is reported to reduce the risk of insulin resistance, aminotransferase levels, dyslipidemia, liver fat and impaired fasting glucose and benefits to glucose-lipid metabolism [19]. Twelve studies are involved in one meta-analysis regarding exercise therapy versus control in NAFLD, and the results reveals the the benefit of exercise therapy on liver fat but not alanine transferase (ALT) levels [20]. Moderate intensity progress resistance training is associated with significant improvement in hepatic fat, subcutaneous fat and insulin sensitivity for NAFLD [9].

One recent meta-analysis compared aerobic with resistance exercise for NAFLD, and the results found that both exercise programs are able to reduce hepatic steatosis in NAFLD with similar frequency, duration, and period of exercise, but significantly lower intensity and energy consumption are needed for resistance exercise than that for aerobic exercise. These data suggest that resistance exercise may be preferred over aerobic exercise for NAFLD patients with poor cardiorespiratory fitness [16]. The use of resistance exercise on NAFLD still has not been well established. Recently, several RCTs on the topic have been published, and the results have been conflicting [21-23]. With accumulating evidence, a systematic review and meta-analysis of RCTs was performed to investigate the efficacy of resistance exercise on NAFLD.

Materials and methods

Ethics approval and patient consent are not required because this is a systematic review and meta-analysis of previously published studies. The systematic review and meta-analysis are conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [24].

Search strategy and study selection

Two investigators independently searched the following databases (inception to March 2018): PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. The electronic search strategy was conducted using the following keywords: resistance training or resistance exercise, and non-alcoholic, and liver disease. Reference lists of the screened full-text studies were also searched to identify other potentially eligible trials.

The inclusive selection criteria are as follows: (i) population: patients with non-alcoholic fattyliver disease; (ii) intervention: resistance exercise; (iii) comparison: usual activities or aerobic activities; (iv) study design: RCT.

Data extraction and outcome measures

The following information was extracted: author, number of patients, age, body mass index, female, body fat and detail methods in each group etc. Data were extracted independently by two investigators, and discrepancies were resolved by consensus. The corresponding author was also contacted to obtain the data when necessary. No simplifications and assumptions are made. The primary outcomes are ALT and aspartate transferase (AST) change. Secondary outcomes include the change of gamma-glutamyl transferase (GGT), cholesterol, low-density lipoprotein (LDL), and glycosylated hemoglobin (HbA1C).

Quality assessment in individual studies

Methodological quality of the included studies was independently evaluated using the modified Jadad scale [25]. There are 3 items for Jadad scale: randomization (0-2 points), blinding (0-2 points), dropouts and withdrawals (0-1 points). The score of Jadad Scale varies from 0 to 5 points. An article with Jadad score \leq 2 is considered to be of low quality. If the Jadad score \geq 3, the study is thought to be of high quality [26].

Statistical analysis

The mean difference (MD) was estimated with 95% confidence interval (CI) for continuous outcomes (ALT, AST, GGT, cholesterol, LDL, and Hb-A1C). A random-effects model was used regardless of heterogeneity. Heterogeneity is reported using the I^2 statistic, and $I^2 > 50\%$ indicates significant heterogeneity [27]. Whenever significant heterogeneity is present, potential sources of heterogeneity were searched via omitting one study in turn for the meta-analysis or performing subgroup analysis. Publication bias is not evaluated because of the limited number (< 10) of included studies. All statistical analyses are performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

Results

Literature search, study characteristics and quality assessment

A detailed flowchart of the search and selection results is shown in **Figure 1**. 556 potentially relevant articles are identified initially. Finally, four RCTs that meet the inclusion criteria are included in the meta-analysis [21-23, 28].

The baseline characteristics of the four eligible RCTs in the meta-analysis are summarized in **Table 1.** The four studies are published between



2011 and 2015, and sample sizes range from 19 to 64 with a total of 133. The detailed intensity of resistance exercise were different in each RCT. The intervention treatments in control group included usual activities [21, 22, 28] and aerobic activities [23].

Among the four studies included here, three studies report ALT and AST [21-23], and two studies report GGT, cholesterol, LDL, and HbA1C [22, 23]. Jadad scores of the four included studies vary from 3 to 5, and all four studies are considered to be high-quality ones according to quality assessment.

Primary outcomes: ALT and AST change

These outcome data are analyzed with the random-effects model, and the pooled estimate of the three included RCTs suggested that compared to control group for non-alcoholic fattyliver disease, resistance exercise can significantly reduce ALT (MD = -6.63; 95% CI = -12.87 to -0.40; P = 0.04), with significant heterogeneity among the studies (I² = 79%, heterogeneity P = 0.008) (**Figure 2**).

Consistently, resistance exercise was associated with substantially decreased AST for nonalcoholic fatty-liver disease (MD = -1.17; 95% Cl = -1.82 to -0.52; P = 0.0004), with low heterogeneity among the studies ($I^2 = 4\%$, heterogeneity P = 0.35) (Figure 3).

Sensitivity analysis

Low heterogeneity was observed among the included studies for AST analysis, but ALT anal-

ysis results in significant heterogeneity. When performing sensitivity analysis via omitting one study in turn, there was still significant heterogeneity.

Secondary outcomes

Compared to the control group for non-alcoholic fattyliver disease, resistance exercise was able to substantially reduce GGT (MD = -2.87; 95% CI = -5.20 to -0.54; P = 0.02; Figure 4), cholesterol (MD = -8.76; 95% CI = -13.08 to -4.44; P < 0.0001; Figure 5), LDL (MD

= -5.06; 95% Cl = -6.25 to -3.87; P < 0.00001; Figure 6), but showed no significant influence on HbA1C (MD = -0.01; 95% Cl = -0.08 to 0.06; P = 0.81; Figure 7).

Discussion

The American Heart Association has recommended resistance exercise as a complement to aerobic exercise [29]. Resistance exercise is reported to significantly reduce steatosis as measured by an objective ultrasonographic tool [28]. The meta-analysis reported here suggests that resistance exercise is able to substantially reduce ALT, AST, and GGT for patients with NA-FLD, but has no important influence on HbA1C.

It is important to understand whether resistance or aerobic training is superior in inducing changes in hepatic fat liver enzymes and body composition in NAFLD. The mechanisms underlying the change in hepatic fat by exercise training have some association with changes in insulin sensitivity, circulatory lipids and energy balance [28]. Insulin sensitivity is very important for internal hepatic lipid homeostasis. Exercise training can increase body glucose disposal partly due to increased expression of GLUT4 in skeletal muscles, insulin receptor and glycogen storage [30]. An 8-week resistance exercise program reveals reduction in liver lipid and HOMA-IR for NAFLD independent of any change in body weight [28]. Another RCT reports that resistance exercise and aerobic exercise are equally effective to decrease hepatic fat content and liver enzyme levels for NAFLD. In addition, aerobic exercise results in

Table 1. Characteristics of included studies

					Resistance exer	rcise group		Control group						lada
NO.	Author	Number	Age (years)	Female (n)	Body mass index (kg/m²)	Body fat (%)	Methods	Number	Age (years)	Female (n)	Body mass index (kg/m²)	Body fat (%)	Methods	scores
1	Shamsoddini 2015, Iran	10	45.9 ± 7.3	-	30.6 ± 2.6	25.6 ± 4.4	Seven resistance exercises at intensity of 50%-70% of 1 repetition maximum	10	45.8 ± 7.3	-	28.2 ± 3.7	23.3 ± 6	No exercise training program	4
2	Zelber-Sagi 2014, Israel	33	46.32 ± 10.32	17	30.75 ± 4.52	-	Resistance exercises, three times weekly, for 3 months	31	46.64 ± 11.4	13	31.30 ± 4.14	-	Home stretching	5
3	Bacchi 2013, Italy	17	56.0 ± 1.9	5	28.8 ±1.1	29.8 ± 1.9	3 series of 10 repetitions at 70%-80% 1- repetition maxi- mum, with 1 minute of recovery between series	13	55.6 ± 2.0	4	30.5 ± 1.0	29.8 ± 1.9	Aerobic activities	4
4	Hallsworth 2011, UK	11	-	-	32.3 ± 4.9	-	Three times per week on non- consecutive days for 8 weeks	8	-	-	32.3 ± 4.8	-	Continued normal treatment	3



Figure 2. Forest plot for the meta-analysis of ALT change (U/L).



Figure 3. Forest plot for the meta-analysis of AST change (U/L).

	Resistance	exercise	group	Control group				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random. 95% C	IV. Random, 95% CI
Bacchi 2013	-1.8	0.36	17	0.69	1.31	13	90.7%	-2.49 [-3.22, -1.76]	
Zelber-Sagi 2014	-4.25	13.03	33	2.35	16.48	31	9.3%	-6.60 [-13.91, 0.71]	
Total (95% CI) 50							100.0%	-2.87 [-5.20, -0.54]	
Heterogeneity: Tau ² = '	1.42; Chi ² = 1	.20, df = 1		-20 -10 0 10 20					
Test for overall effect: Z = 2.41 (P = 0.02)									Favours [experimental] Favours [control]

Figure 4. Forest plot for the meta-analysis of GGT change (U/L).



Figure 5. Forest plot for the meta-analysis of cholesterol change (mg/dL).

	Resistance	e exercise	group	Control group				Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random. 95% CI		IV.	Rando	m. 95% CI		
Bacchi 2013	3.4	0.95	17	8.4	2.04	13	98.7%	-5.00 [-6.20, -3.80]						
Zelber-Sagi 2014	-6.09	26.38	33	3.61	14.57	31	1.3%	-9.70 [-20.06, 0.66]						
Total (95% CI)		44	100.0%	-5.06 [-6.25, -3.87]			•							
Heterogeneity: Tau ² = 0.00; Chi ² = 0.78, df = 1 (P = 0.38); l ² = 0%									-50	-25	0		25	50
Test for overall effect: Z = 8.34 (P < 0.00001)									Favou	rs [experim	ental]	Favours [co	ontrol]	00

Figure 6. Forest plot for the meta-analysis of LDL change (mg/dL).

	Resistance exercise group				rol gro	oup		Mean Difference		nce			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rar	ndom. 9	5% CI	
Bacchi 2013	-0.32	0.03	17	-0.34	0.04	13	59.9%	0.02 [-0.01, 0.05]			•		
Zelber-Sagi 2014	-0.01	0.13	33	0.04	0.14	31	40.1%	-0.05 [-0.12, 0.02]			-		
Total (95% CI)			50			44	100.0%	-0.01 [-0.08, 0.06]			•		
Heterogeneity: Tau ² = 0.00; Chi ² = 3.71, df = 1 (P = 0.05); l ² = 73% Test for overall effect: Z = 0.24 (P = 0.81)									-1 Fav	-0.5 ours [experimenta	0 al] Fav	0.5 ours [control]	1

Figure 7. Forest plot for the meta-analysis of HbA1C change (%).

special improvement for NAFLD independent of any change in body weight [21].

Liver steatosis is associated with insulin resistance and lipid abnormalities [31, 32]. Increased insulin resistance contributes to the shift in cholesterol metabolism independent of body weight [33, 34]. Resistance training is found to improve insulin resistance including hepatic insulin resistance, and results in decreased synthesis of hepatic cholesterol [35, 36]. The precise mechanisms involving these processes remain elusive [37]. Lipid markers (i.e. cholesterol and LDL) is significantly decreased by resistance training in patients with NAFLD based on the results of our meta-analysis. There was still significant heterogeneity after performing sensitivity analysis via omitting one study in turn, and the possible explanations include the different methods and duration of resistance exercise, methods of control group and patients with various body mass index.

This meta-analysis has several potential limitations that should be taken into account. First, analysis is based on only four RCTs and all of them have a relatively small sample size (n < 100). More RCTs with large samples should be conducted to confirm this issue. Next, there is significant heterogeneity when performing sensitivity analysis, different methods and duration of resistance exercise and patient populations may have an influence on the pooling results. Finally, the diagnosis of is not based on histology in included RCTs, and the fat content is not measured by biopsy.

Conclusions

Resistance exercise can provide important benefits to patients with NAFLD, and should be recommended in clinical work.

Disclosure of conflict of interest

None.

Address correspondence to: Xiaoping Yang, Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, No. 318 Chaowang Road, Hangzhou 310005, Zhejiang Province, China. Tel: 0086057483870999; Fax: 008605748-3870999; E-mail: yangxiaoping2007@suhou.com

References

[1] Ghamar-Chehreh ME, Khedmat H, Amini M and Taheri S. Predictive factors for ultrasonographic grading of nonalcoholic fatty liver disease. Hepat Mon 2012; 12: e6860.

- [2] Francque S, Lanthier N, Verbeke L, Reynaert H, Van Steenkiste C, Vonghia L, Kwanten WJ, Weyler J, Trépo E, Cassiman D, Smets F, Komuta M, Driessen A, Dirinck E, Danse E, Op de Beeck B, van Craenenbroeck E, Van Nieuwenhove Y, Hubens G, Geerts A and Moreno C. The belgian association for study of the liver guidance document on the management of adult and paediatric non-alcoholic fatty liver disease. Acta Gastroenterol Belg 2018; 81: 55-81.
- [3] Atay K, Canbakan B, Koroglu E, Hatemi I, Canbakan M, Kepil N, Tuncer M and Senturk H. Apoptosis and disease severity is associated with insulin resistance in non-alcoholic fatty liver disease. Acta Gastroenterol Belg 2017; 80: 271-277.
- [4] St George A, Bauman A, Johnston A, Farrell G, Chey T and George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68-76.
- [5] Patel S, Lawlor DA, Callaway M, Macdonald-Wallis C, Sattar N and Fraser A. Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatr 2016; 16: 47.
- [6] Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP and Cushman M. Nonalcoholic fatty liver disease, liver biomarkers and stroke risk: the reasons for geographic and racial differences in stroke cohort. PLoS One 2018; 13: e0194153.
- [7] Botero P, Hoy EM, Jimenez MC, Koru-Sengul T and Messiah SE. Predictors of non-alcoholic liver disease in ethnically diverse overweight children and adolescents. Curr Pediatr Rev 2018; 14: 130-135.
- [8] Chitturi S, Wong VW and Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26 Suppl 1: 163-72.
- [9] Damor K, Mittal K, Bhalla AS, Sood R, Pandey RM, Guleria R, et al. Effect of progressive resistance exercise training on hepatic fat in Asian Indians with non-alcoholic fatty liver disease. British J Med Res 2014; 4: 114-24.
- [10] Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G and Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009; 29: 159-63.
- [11] Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, Oddy WH, Shipman P and Adams LA. Gender-specific differences in

adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800-9.

- [12] Tolman KG and Dalpiaz AS. Treatment of nonalcoholic fatty liver disease. Ther Clin Risk Manag 2007; 3: 1153-63.
- [13] Saleh DA, Ismail MA and Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci 2012; 15: 68-77.
- [14] Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E and Nagabukuro H. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2018; 497: 207-213.
- [15] Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H and Niu J. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trials. Medicine 2017; 96: e9061.
- [16] Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, Takano Y, Ueno T, Koga H, George J, Shiba N and Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017; 66: 142-152.
- [17] Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106: 460-8; quiz 9.
- [18] American Gastroenterological Association. American gastroenterological association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.
- [19] Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A and Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21: 191-8.
- [20] Keating SE, Hackett DA, George J and Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157-66.
- [21] Shamsoddini A, Sobhani V, Ghamar Chehreh ME, Alavian SM and Zaree A. Effect of aerobic and resistance exercise training on liver enzymes and hepatic fat in iranian men with nonalcoholic fatty liver disease. Hepat Mon 2015; 15: e31434.

- [22] Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, Kis O, Fliss-Isakov N, Izkhakov E, Halpern Z, Santo E, Oren R and Shibolet O. Effect of resistance training on non-alcoholic fatty-liver disease a randomizedclinical trial. World J Gastroenterol 2014; 20: 4382-92.
- [23] Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, Zanolin E, Schena F, Bonora E and Moghetti P. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology 2013; 58: 1287-95.
- [24] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
- [25] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, Gavaghan DJ and McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
- [26] Kjaergard LL, Villumsen J and Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
- [27] Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
- [28] Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP and Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-83.
- [29] Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA, Gulanick M, Laing ST, Stewart KJ; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American heart association council on clinical cardiology and council on nutrition, physical activity, and metabolism. Circulation 2007; 116: 572-84.
- [30] Jensen J, Rustad PI, Kolnes AJ and Lai YC. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol 2011; 2: 112.
- [31] Wasada T, Kasahara T, Wada J, Jimba S, Fujimaki R, Nakagami T and Iwamoto Y. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in

the early stage of obesity. Metabolism 2008; 57: 980-5.

- [32] Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, Chaves PH, Jonsdottir B, Garcia M, Gudnason V, Harris TB; AGES-Reykjavik Study Investigators. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity 2011; 19: 1265-71.
- [33] Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, Lundbom N, Miettinen TA, Gylling H and Yki-Järvinen H. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54: 153-9.
- [34] Flannery C, Dufour S, Rabol R, Shulman Gl and Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 2012; 61: 2711-7.

- [35] Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME and Castaneda-Sceppa C. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. Int J Med Sci 2006; 4: 19-27.
- [36] Van Der Heijden GJ, Wang ZJ, Chu Z, Toffolo G, Manesso E, Sauer PJ and Sunehag AL. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010; 42: 1973-80.
- [37] Mann S, Beedie C and Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med 2014; 44: 211-21.